• AIM Vaccine enlisted for important contracted project for “Two-zone” construction in Beijing with introduced investments


    On the morning of September 3, Zhou Ting, Board Chairman and CEO of AIM Vaccine Co., Ltd attended “One-day for Beijing” and anniversary celebration of “Two-zone” construction at 2021 China International Fair for Trade in Services under invitation, and participated in the signing ceremony for “Two-zone” project. PRC head office and phase-1 project innovative vaccine industrialization base of AIM Vaccine have been listed as important contracted projects for “two-zone” construction in Beijing with introduced investments through strict screening. It is one of 37 key projects completed contract conclusion with Beijing Economic-Technological Development Area t the site on the current day.

  • AIM COVID-19 vaccine achieved critical progress in industrialization


    Ningbo Rong’an Biological Pharmaceutical Co., Ltd, the wholly owned subsidiary of AIM Vaccine has recently obtained Approval Form of Clinical Trial as approved and issued by National Medical Products Administration.

  • AIM Vaccine completed acquisition of Lifanda to accelerate deployment of mRNA COVID-19 Vaccine


    On May 31, AIM Vaccine Co., Ltd completed acquisition of Zhuhai Lifanda Biology Co., Ltd, holding 50.1546% of its shares. Lifanda Biology is one of 3 enterprises obtained clinical approval of mRNA COVID-19 vaccine.

1 2 3 4

Media Inquiry

Email to:mediacenter@aimbio.com